Solana Business Summary

Solana Co (HSDT), formerly Helius Medical Technologies, operates a dual-segment business model centered on its transition into a premier digital asset treasury dedicated to the Solana (SOL) ecosystem. The company generates revenue primarily through native staking rewards—leveraging an approximate 7% yield on its SOL holdings—and is aggressively expanding into on-chain activities including liquid staking, automated market makers (AMMs), and RPC services, particularly within the Asia-Pacific region via its "Pacific Backbone" infrastructure. While the firm maintains its legacy neurotech segment, which develops the PoNS device for neuromodulation, its primary growth engine is the systematic accumulation of SOL reserves to maximize value per share for public market investors. Direct competitors include Forward Industries, Bitmine, and Prenetics; Solana Co distinguishes itself as a high-conviction, publicly traded proxy for Solana, mirroring the "MicroStrategy model" for the SOL token. The company’s strategic pivot is led by Executive Chairman and CEO Joseph Chee, a veteran investment banker who previously served as the Head of Global Capital Markets for Asia at UBS and founded Summer Capital. He is supported by President Dane Andreeff, the founder of Maple Leaf Partners, and CFO Jeffrey S. Mathiesen, who brings extensive experience in medical device and semiconductor finance. The leadership team is bolstered by a strategic partnership with Pantera Capital, represented by Director Cosmo Jiang, a General Partner at Pantera, and Strategic Advisor Dan Morehead, Pantera’s founder and a pioneer in institutional blockchain investing. This team combines deep traditional finance pedigree from firms like Goldman Sachs and Tiger Management with specialized crypto-native treasury management to drive the company's institutional-grade digital asset strategy.